Global Hospital Acquired Disease Testing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2015 to 2022

  • ID: 4313274
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Becton Dickinson
  • bioMerieux
  • Cantel
  • Cepheid
  • Diatherix
  • Nordion
  • MORE
Hospital Acquired Disease Testing Market Growth, Future Prospects and Competitive Analysis, 2016-2022, the hospital acquired disease testing market was valued at USD 523.0 Mn in 2015, and is expected to reach USD 1,630.0 Mn by 2022, expanding at a CAGR of 5.4% from 2016 to 2022.

Market Insights
Hospital acquired infections/diseases (HAIs) or nosocomial infections are defined to the infection acquired by patients during their stay in healthcare settings. Approximately 9.2 out of 100 patients in the U.S. acquire HAI. The most common types of HAIs include pneumonia, urinary tract infection, bloodstream infection, surgical site infection and others. HAIs are caused by pathogens among patients with compromised immune system, and negligence by hospital staff. The significant morbidity and mortality, the associated management costs and growing pressure from governing bodies have urged care-givers to devise accurate diagnosis of HAIs for efficient healthcare provision.

The global hospital acquired disease testing market is categorized into tests for hospital acquired pneumonia, urinary tract infection, surgical site infection, bloodstream infection, MRSA and others. Hospital acquired pneumonia and urinary tract infection together occupy more over 50% market share in 2015 with a larger set of revenue coming from urinary tract infection. The prevalence and morbidity associated with urinary tract infection is the highest among the other infection types and its diagnosis is the swiftest. It is anticipated that the dominance of this segment will continue through the forecast period 2016-2022. Other testing tools for surgical site infections and bloodstream infection are anticipated to undergo faster growth during the forecast period attributed by their alarming incidence in the emerging markets.

Geographically, North America is the largest regional market for hospital acquired disease testing, high number of hospital stays and the corresponding risk of contracting HAIs majorly determine the market size of this region. On the other hand, greater awareness and reducing the incidence of hospital readmission, along with the growing urgency to control hospital and healthcare costs contribute to the faster market growth rate of Asia-Pacific and Latin America hospital acquired disease testing markets.

In view of the market competition, this market is fragmented with a multitude of companies offering HAI testing tools. Some of the notable players in the hospital acquired disease testing market include Diatherix Corp, Roche, Cantel Medical Corporation, Qiagen, Cephid, bioMeriux and others.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Becton Dickinson
  • bioMerieux
  • Cantel
  • Cepheid
  • Diatherix
  • Nordion
  • MORE
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Hospital Acquired Disease Testing Market, by Infection Type, 2015 (USD Mn)
2.2 Hospital Acquired Disease Testing Market Share, by Geography, 2015 (Value %)

Chapter 3 Hospital Acquired Disease Testing Market: Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.2 Drivers
3.3 Challenges
3.4 Future Prospects
3.5 Attractive Investment Proposition
3.1 Competitive Analysis: Fractal Map Investigation, by Key Market Players

Chapter 4 Global Hospital Acquired Disease Testing Market Analysis, by Infection Type
4.1 Preface
4.2 Pneumonia
4.3 Urinary Tract Infection
4.4 Blood Stream Infection
4.5 Surgical Site Infection
4.6 Mrsa
4.7 Others

Chapter 5 Global Hospital Acquired Disease Testing Market, by Geography
5.1 Preface
5.2 North America
5.3 Europe
5.4 Asia-Pacific
5.5 Middle East and Africa (Mea)
5.6 Latin America

Chapter 6 Company Profiles
6.1 Becton Dickinson
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Positions/Portfolio
6.1.4 News Coverage
6.2 Biomerieux
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Positions/Portfolio
6.2.4 News Coverage
6.3 Cantel
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Positions/Portfolio
6.3.4 News Coverage
6.4 Cepheid
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Positions/Portfolio
6.4.4 News Coverage
6.5 Diatherix
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Positions/Portfolio
6.5.4 News Coverage
6.6 Qiagen
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product Positions/Portfolio
6.6.4 News Coverage
6.7 Nordion
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Positions/Portfolio
6.7.4 News Coverage
6.8 Roche
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Positions/Portfolio
6.8.4 News Coverage
6.9 Others
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Positions/Portfolio
6.9.4 News Coverage

List of Figures
Figure 1 Hospital Acquired Disease Testing: Market Segmentation
Figure 2 Hospital Acquired Disease Testing Market, by Infection Type, 2015 (USD Mn)
Figure 3 Hospital Acquired Disease Testing Market Share, by Geography, 2015 (Value %)
Figure 4 Attractive Investment Proposition, Hospital Acquired Disease Testing Market, 2015
Figure 5 Competitive Analysis: Fractal Map Investigation, by Key Market Players
Figure 6 Global Hospital Acquired Pneumonia Testing Market, 2014 - 2022 (USD Mn)
Figure 7 Global Hospital Acquired Urinary Tract Infection Testing Market, 2014 - 2022 (USD Mn)
Figure 8 Global Hospital Acquired Blood Stream Infection Testing Market, 2014 - 2022 (USD Mn)
Figure 9 Global Hospital Acquired Surgical Site Infection Market, 2014 - 2022 (USD Mn)
Figure 10 Global Mrsa Testing Market, 2014 - 2022 (USD Mn)
Figure 11 Global Other Hospital Acquired Diseases Testing Market, 2014 - 2022 (USD Mn)
Figure 12 U.S. Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
Figure 13 Canada Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
Figure 14 U.K. Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
Figure 15 Germany Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
Figure 16 Rest of Europe Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
Figure 17 Japan Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
Figure 18 China Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
Figure 19 Rest of Asia-Pacific Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
Figure 20 Middle East and Africa Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
Figure 21 Latin America Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)

List of Tables
Table 1 Global Hospital Acquired Disease Testing Market, by Infection Type, 2014 - 2022 (USD Mn)
Table 2 Global Hospital Acquired Disease Testing Market, by Geography, 2014 - 2022 (USD Mn)
Table 3 North America Hospital Acquired Disease Testing Market, by Country, 2014 - 2022 (USD Mn)
Table 4 Europe Hospital Acquired Disease Testing Market, by Country, 2014 - 2022 (USD Mn)
Table 5 Asia-Pacific Hospital Acquired Disease Testing Market, by Country, 2014 - 2022 (USD Mn)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Becton Dickinson
  • bioMerieux
  • Cantel
  • Cepheid
  • Diatherix
  • Qiagen
  • Nordion
  • Roche
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll